Drug intelligence / Profile preview

5-HT1A agonist (Suven Life Sciences)

Development stage: Preclinical
Lead developer: Suven Life Sciences
Modality: Small Molecules

Overview

5-HT1A agonist (Suven Life Sciences) is a small molecule serotonin 1A (5-HT1A) receptor agonist currently in preclinical development by Suven Life Sciences. The drug is being investigated for the treatment of treatment-resistant depression (TRD). By targeting the 5-HT1A receptor, the compound aims to modulate serotonergic signaling in the central nervous system, a mechanism often utilized to address depressive symptoms that have not responded to standard antidepressant therapies. As of the latest pipeline updates, the program is in the lead optimization stage.

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on 5-HT1A agonist (Suven Life Sciences).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-HT1A agonist (Suven Life Sciences).

Explore the full profile